Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Cipla Ltd ( (IN:CIPLA) ).
Cipla Ltd has announced that its wholly owned subsidiary, Sitec Labs Limited’s analytical testing facility in Mahape, Navi Mumbai, was recently inspected by the USFDA. The inspection, which took place from February 18 to 20, 2025, resulted in two observations being noted in Form 483. Cipla is committed to addressing these observations comprehensively in collaboration with the USFDA, emphasizing the company’s dedication to maintaining compliance with global manufacturing standards.
More about Cipla Ltd
Cipla Ltd is a major player in the pharmaceutical industry, focusing on the development and manufacturing of a wide range of pharmaceutical products. The company is known for its commitment to high-quality, affordable healthcare solutions and has a significant presence in both domestic and international markets.
YTD Price Performance: -4.36%
Average Trading Volume: 60,184
Current Market Cap: 1197B INR
For an in-depth examination of CIPLA stock, go to TipRanks’ Stock Analysis page.
